NZ781774A - Stable topical compositions of fenoldopam - Google Patents

Stable topical compositions of fenoldopam

Info

Publication number
NZ781774A
NZ781774A NZ781774A NZ78177420A NZ781774A NZ 781774 A NZ781774 A NZ 781774A NZ 781774 A NZ781774 A NZ 781774A NZ 78177420 A NZ78177420 A NZ 78177420A NZ 781774 A NZ781774 A NZ 781774A
Authority
NZ
New Zealand
Prior art keywords
fenoldopam
composition
topical compositions
stable topical
stable
Prior art date
Application number
NZ781774A
Other languages
English (en)
Inventor
Helena Shifrin
Alexandra Shraifel
Vered Rosenberger
Ron Schlinger
Tzviel Sheskin
Avi Avramoff
Original Assignee
Taro Pharma Ind
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taro Pharma Ind filed Critical Taro Pharma Ind
Publication of NZ781774A publication Critical patent/NZ781774A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ781774A 2019-03-08 2020-03-06 Stable topical compositions of fenoldopam NZ781774A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962815893P 2019-03-08 2019-03-08
PCT/IB2020/051967 WO2020183322A1 (en) 2019-03-08 2020-03-06 Stable topical compositions of fenoldopam

Publications (1)

Publication Number Publication Date
NZ781774A true NZ781774A (en) 2023-03-31

Family

ID=69846519

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ781774A NZ781774A (en) 2019-03-08 2020-03-06 Stable topical compositions of fenoldopam

Country Status (11)

Country Link
US (2) US11446237B2 (https=)
EP (2) EP3908255B1 (https=)
JP (2) JP7124234B2 (https=)
CN (2) CN116966129A (https=)
AU (2) AU2020236525B2 (https=)
BR (1) BR112021017140A2 (https=)
CA (1) CA3131049A1 (https=)
ES (1) ES2941241T3 (https=)
IL (1) IL286197A (https=)
NZ (1) NZ781774A (https=)
WO (1) WO2020183322A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2023257375A1 (en) 2022-04-21 2024-11-07 Glaukos Corporation Ophthalmic topical cream compositions

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
ATE210975T1 (de) 1994-06-23 2002-01-15 Procter & Gamble Topisch anzuwendende zubereitungen enthaltend n- acetyl-l-cystein
US6054429A (en) 1996-03-08 2000-04-25 Elan Pharmaceuticals, Inc. Epidural method of producing analgesia
AU3869399A (en) 1998-04-27 1999-11-16 Elan Pharmaceuticals, Inc. Transdermal administration of fenoldopam
JPH11335236A (ja) 1998-05-22 1999-12-07 Shiseido Co Ltd 皮膚外用剤
EP1100476B1 (en) * 1998-07-24 2004-06-16 ALZA Corporation Formulations for the transdermal administration of fenoldopam
US6699497B1 (en) 1998-07-24 2004-03-02 Alza Corporation Formulations for the transdermal administration of fenoldopam
US7442369B1 (en) * 2000-08-09 2008-10-28 Mcneil Ab Compositions of minoxidil
US7358236B1 (en) 2002-06-21 2008-04-15 Oxigene, Inc. Control of acute hypertension and cardiotoxicity in patients treated with vascular targeting agents
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
WO2005079851A2 (en) 2004-02-18 2005-09-01 Sepracor, Inc. Dopamine-agonist combination therapy with sedatives for improving sleep quality
WO2005108387A2 (en) 2004-05-03 2005-11-17 Boehringer Ingelheim Pharmaceuticals, Inc. Cytokine inhibitors
CN101151028A (zh) * 2005-03-03 2008-03-26 Isw集团公司 局部用凝胶组合物
AU2006265002B2 (en) 2005-06-30 2012-09-20 Centocor, Inc. Anti-IL-23 antibodies, compositions, methods and uses
JP2009502206A (ja) 2005-08-03 2009-01-29 ミニュー・セラピューティクス・リミテッド 腫瘍壊死因子アルファ（ＴＮＦ−α）合成および分泌を調節するための、Ｔ細胞におけるＫｖ１．１電位依存性カリウムチャンネルのモデュレーション、およびＴＮＦ−αの有害な高または低レベルを介しての人の疾患または傷害の治療
WO2009052491A2 (en) 2007-10-18 2009-04-23 Geraghty, Erin Fenoldopam formulations and prodrug derivatives
WO2009072007A2 (en) 2007-12-07 2009-06-11 Foamix Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
WO2009076553A1 (en) 2007-12-11 2009-06-18 Monroe Stephen H Composition of aqueous buffer solution for the treatment of cellular environment and ion channels and methods for using same
CA2732439A1 (en) 2008-07-31 2010-02-04 Case Western Reserve University Halogen-stabilized insulin
JP2011144143A (ja) 2010-01-15 2011-07-28 Shiseido Co Ltd 皮膚外用剤
RU2571277C2 (ru) 2010-10-21 2015-12-20 Галдерма С.А. Композиции геля с бримонидином и способы применения
HUE034480T2 (en) 2011-04-28 2018-02-28 Platform Brightworks Two Ltd Improved parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same
FR2991177B1 (fr) 2012-06-01 2014-12-19 Galderma Res & Dev Compositions topiques, contenant un retinoide, de type emulsion huile dans eau sans emulsionnant
AU2014227996B2 (en) * 2013-03-15 2018-08-23 Vapogenix, Inc. Novel analgesic compositions
JP6893075B2 (ja) 2014-08-04 2021-06-23 日東電工株式会社 液性免疫誘導促進用組成物及びワクチン医薬組成物
UA121985C2 (uk) * 2015-01-23 2020-08-25 Др. Редді'З Лабораторіз Лімітед Нефарбуюча гелева композиція для місцевого застосування, яка містить німесулід
EP3506906A4 (en) * 2016-08-31 2020-08-12 Taro Pharmaceutical Industries Ltd. TOPICAL FORMULATIONS OF FENOLDOPAM FOR THE TREATMENT OF SKIN DISORDERS
MX2020004187A (es) * 2017-10-24 2020-09-21 Glenmark Pharmaceuticals Ltd Composicion farmaceutica topica de adapaleno y minociclina.

Also Published As

Publication number Publication date
EP4218719A2 (en) 2023-08-02
EP3908255B1 (en) 2023-01-11
WO2020183322A1 (en) 2020-09-17
ES2941241T3 (es) 2023-05-19
JP2022160648A (ja) 2022-10-19
CN113543773B (zh) 2023-07-14
EP3908255A1 (en) 2021-11-17
BR112021017140A2 (pt) 2021-11-09
US20230059107A1 (en) 2023-02-23
AU2022202941A1 (en) 2022-05-26
EP4218719A3 (en) 2023-09-20
US11446237B2 (en) 2022-09-20
CN116966129A (zh) 2023-10-31
JP2022515569A (ja) 2022-02-18
AU2020236525B2 (en) 2022-02-03
CA3131049A1 (en) 2020-09-17
IL286197A (en) 2021-10-31
CN113543773A (zh) 2021-10-22
AU2020236525A1 (en) 2021-11-04
JP7124234B2 (ja) 2022-08-23
US20220040089A1 (en) 2022-02-10

Similar Documents

Publication Publication Date Title
MY206908A (en) Cationic lipid compound, composition containing same and use thereof
MX2020008173A (es) Combinacion de un agente antimuscarinico o de uno anticolinergico y acido lipoico, y sus usos.
MX2023000316A (es) Composiciones farmaceuticas y metodos para el tratamiento de la enfermedad de parkinson.
BRPI0805634A2 (pt) composição de concentrado de suspensão (sc) aquosa, método para prepararum concentrado de suspensão, composição de proteção de cultura, método para proteger culturas no local , uso de composição e método para impedir aglomeração de partìculas em um concentrado de suspensão
BRPI0609515A8 (pt) Composto, composição farmacêutica, e, uso de um composto
ZA200501715B (en) Solution for ungual application
MX2009003042A (es) Composiciones farmaceuticas acuosas auto-preservadas.
ATE544444T1 (de) Zusammensetzungen für die nasale abgabe
MX2023010248A (es) Composiciones de acido ascorbico estables y metodos de uso de las mismas.
MX2020002437A (es) Composicion farmaceutica para el suministro de peptidos.
PH12020551342A1 (en) Saturated-ring-fused dihydropyrimidinone or dihydrotriazinone compounds and pharmaceutical use thereof
WO2018231718A8 (en) Dermal filler
MX2025011277A (es) Derivado de amina ciclica y composicion y uso del mismo
WO2019221815A8 (en) Compositions of fosaprepitant and methods of preparation
NZ781774A (en) Stable topical compositions of fenoldopam
JOP20240055A1 (ar) عقار أولي من مشتقات بيروليدون كمنشط جلوكوكيناز
MY199648A (en) Composition of fused tricyclic gamma-amino acid derivatives and the preparation thereof
ZA202308388B (en) Nasal compositions comprising alcaftadine
DK1358883T3 (da) Reepiteliserende farmaceutiske sammensætninger indeholdende xanthangummi
EA200401298A1 (ru) Жидкие фармацевтические композиции, содержащие низкую дозу энтекавира, и их применение
WO2008015189A3 (en) Fungicidal n-cycloalkyl-carboxamide derivatives
MX2021011572A (es) Composicion farmaceutica topica en forma de gel acuoso que contiene por lo menos amitriptilina.
ATE241983T1 (de) Paracetamol und drotaverin enthaltende zusammensetzung
HUP0301378A2 (hu) Tiotropiumsót tartalmazó inhalációs oldatformájú gyógyszerkészítmény
DE69919762D1 (de) R-Metalaxyl enthaltende fungizide Zusammensetzungen

Legal Events

Date Code Title Description
S35A Application for proceedings under section 35 (restoration of lapsed patents)
S35R Proceedings under section 35 (restoration of lapsed patents): patent restored
PSEA Patent sealed
LAPS Patent lapsed